Claritin and Daliresp drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Claritin (loratadine) and Daliresp (roflumilast). Common drug interactions include hypoaesthesia oral among females and breath sounds among males.

The phase IV clinical study analyzes what interactions people have when they take Claritin and Daliresp. It is created by eHealthMe based on reports of 78 people who take the same drugs from the FDA, and is updated regularly.

What is Claritin?

Claritin has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 77,315 Claritin users. Check the latest studies of Claritin.

What is Daliresp?

Daliresp has active ingredients of roflumilast. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 4,722 Daliresp users. Check the latest studies of Daliresp.



On Jul, 12, 2026

78 people who take Claritin and Daliresp together, and have interactions are studied.

Claritin and Daliresp drug interactions.

What are the common drug interactions of Claritin and Daliresp, by gender? *:

female:

  1. Hypoaesthesia oral (reduced sense of touch or sensation in mouth)
  2. Infusion related reaction
  3. Multiple allergies (allergy to multiple agents)
  4. Nephrogenic anaemia (anaemia due to kidney disease)
  5. Oxygen consumption increased
  6. Procedural nausea
  7. Procedural pain
  8. Renal injury (kidney injury)
  9. Sepsis (a severe blood infection that can lead to organ failure and death)
  10. Device related infection

male:

  1. Breath sounds
  2. Dyspnoea (difficult or laboured respiration)
  3. Renal failure (kidney dysfunction)
  4. Anaemia (lack of blood)
  5. Asthenia (weakness)
  6. Back pain
  7. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  8. Blood glucose increased
  9. Blood pressure increased
  10. Blood triglycerides increased

What are the common drug interactions of Claritin and Daliresp, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Breath sounds
  2. Blood glucose increased
  3. Blood pressure increased
  4. Blood triglycerides increased
  5. Cough
  6. Dyspnoea (difficult or laboured respiration)
  7. Epistaxis (bleed from the nose)
  8. Gout (uric acid crystals building up in the body)
  9. Gouty arthritis (joint inflammation with crystal formation)
  10. Lipids increased (excess lipid in body)

50-59:

  1. Memory impairment
  2. Meningitis aseptic (a condition that causes the membranes covering your brain and spinal cord to become inflamed)
  3. Pneumonia
  4. Pruritus (severe itching of the skin)
  5. Respiratory tract infection
  6. Sinusitis (inflammation of sinus)
  7. Chronic kidney disease
  8. Nephrogenic anaemia (anaemia due to kidney disease)
  9. Renal failure (kidney dysfunction)
  10. Renal injury (kidney injury)

60+:

  1. Fatigue (feeling of tiredness)
  2. Dizziness
  3. Arthralgia (joint pain)
  4. Chest discomfort
  5. Chest pain
  6. Costochondritis (chest wall pain)
  7. Cough
  8. Death
  9. Eye swelling
  10. Fall

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 10.26%
  2. Immunodeficiency Common Variable: 7 people, 8.97%
  3. Asthma: 7 people, 8.97%
  4. Pain: 6 people, 7.69%
  5. High Blood Pressure: 5 people, 6.41%
  6. Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 5 people, 6.41%
  7. Wheezing (a high-pitched whistling sound made while you breath): 4 people, 5.13%
  8. Multiple Allergies (allergy to multiple agents): 4 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Claritin and Daliresp?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Claritin and Daliresp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Claritin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Daliresp:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Claritin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Daliresp and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on loratadine and roflumilast (the active ingredients of Claritin and Daliresp, respectively), and Claritin and Daliresp (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: